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2014, accepted Mahe use of extracorporeal membrane oxygenation (ECMO) for both respiratory and cardiac failure in adults is
evolving rapidly. Advances in technology and accumulating data are spurring greater interest and explosive growth in
ECMO worldwide. Expanding indications and novel strategies are being used. Yet the use of ECMO outpaces the
data. The promise of a major paradigm shift for the treatment of respiratory and cardiac failure is tempered
by a need for evidence to support many current and potential future uses. The authors review cannulation strategies,
indications, and evidence for ECMO in respiratory and cardiac failure in adults as well as potential applications and
the impact they may have on current treatment paradigms. (J Am Coll Cardiol 2014;63:2769–78) ª 2014 by the
American College of Cardiology FoundationAlthough extracorporeal membrane oxygenation (ECMO) has
been in existence since the 1970s as a means of supporting
respiratory or cardiac function, early application of this tech-
nology was plagued by high complication rates, with no proven
survival advantage over conventional management (1,2). Major
recent advances in extracorporeal technology have favorably
altered its risk-beneﬁt proﬁle (3–6), and an expanding body
of evidence and more extensive experience have generated
renewed interest as well as a considerable rise in the use of
ECMO for cardiopulmonary disease (7,8). In this review, we
discuss the cannulation strategies, indications, and evidence for
the initiation of ECMO in cardiopulmonary disease, along
with potential future applications that could shift the paradigm
in approaches to both respiratory and cardiac failure.Conﬁgurations and Cannulation Strategies
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rch 4, 2014.oxygenator, a gas exchange device that uses a semipermeable
membrane to separate a blood compartment from a gas
compartment. Deoxygenated blood is withdrawn through a
drainage cannula by an external pump, passes through the
oxygenator, and is returned to the patient through a rein-
fusion cannula. When blood is drained from a central vein
and returned to a central vein, a process known as venove-
nous ECMO, the device is providing gas exchange only.
When blood is drained from the venous system and pumped
into an artery, a process known as venoarterial ECMO, the
circuit provides both respiratory and circulatory support.
The amount of blood ﬂow through the circuit, the fraction
of oxygen delivered through the oxygenator, and the
contribution of the native lungs are the main determinants
of blood oxygenation for a given device, whereas the rate of
gas ﬂow through the oxygenator, known as the sweep gas
ﬂow rate, and the blood ﬂow rate are the major determinants
of carbon dioxide removal (9). Extracorporeal circuits are
very efﬁcient at removing carbon dioxide and can do so at
blood ﬂow rates much lower than what is needed to achieve
adequate oxygenation (10,11). Therefore, when the goal is
extracorporeal carbon dioxide removal (ECCO2R), smaller
cannulae can be used, which may be easier and safer to
insert (12). ECCO2R may be used to address hypercapnic
respiratory failure or to eliminate carbon dioxide in pri-
marily hypoxemic respiratory failure to permit reduced
ventilation strategies. An alternative conﬁguration used
primarily for carbon dioxide removal is arteriovenous
ECCO2R, in which the patient’s native cardiac output
generates blood ﬂow through the circuit, without the need
for an external pump (13).
Traditional venovenous ECMO conﬁgurations involve
cannulation at 2 distinct venous access points for drainage
and reinfusion of blood (9) (Fig. 1). This conﬁguration,
Figure 1
Two-Site Venovenous Extracorporeal Membrane
Oxygenation
Venous blood is withdrawn from a central vein, pumped through an oxygenator,
and reinfused into a central vein. (Inset) Drainage and reinfusion ports in close
proximity may lead to oxygenated blood being drawn back into the circuit without
having entered the systemic circulation, known as recirculation (purple arrow).
Abbreviations
and Acronyms
ARDS = acute respiratory
distress syndrome
CPR = cardiopulmonary
resuscitation
ECCO2R = extracorporeal
carbon dioxide removal
ECMO = extracorporeal
membrane oxygenation
ECPR = extracorporeal
cardiopulmonary
resuscitation
LVAD = left ventricular
assist device
PCI = percutaneous coronary
intervention
PGF = primary graft failure
VAD = ventricular assist
device
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2770with the drainage and infusion
ports in close approximation, may
lend itself to drawing reinfused,
oxygenated blood back into the
circuit, a phenomenon known as
recirculation. Recirculated blood
does not contribute to systemic
oxygenation. Additionally, 2-site
venovenous ECMO requires fe-
moral access. With the advent of
bicaval dual-lumen cannulae, the
internal jugular vein can be used
as the lone venous access site to
provide venovenous extracorporeal
support, avoiding femoral can-
nulation altogether (5,6) (Fig. 2).
This approach requires the proper
positioning of the cannula, with
the reinfusion port oriented such
that ﬂow is directed across the
tricuspid valve, minimizing theFigure 2
Single-Site Venovenous Extracorporeal Membrane
Oxygenation
A dual-lumen cannula in the internal jugular vein permits both venous drainage and
reinfusion without the need for femoral cannulation. (Inset) Deoxygenated blood is
withdrawn through ports in the superior and inferior vena cavae. The reinfusion
port is oriented such that oxygenated blood is directed toward the tricuspid valve.amount of recirculation (6). Placement is typically accom-
plished under ﬂuoroscopic or transesophageal echocardio-
graphic guidance (14). For patients in whom mobilization is
anticipated, particularly those awaiting transplantation
whose candidacy depends in part on their physical condi-
tioning, a conﬁguration that avoids femoral cannulation is
preferred. Cannula size is based on the physiologic needs of
the patient, and particular consideration should be given to
the patient’s estimated cardiac output. For a given extra-
corporeal blood ﬂow, changes in cardiac output will alter the
percent of the patient’s blood volume passing through the
oxygenator, which will affect systemic oxygenation.
In patients with signiﬁcantly impaired cardiac function,
with or without impaired gas exchange, a venoarterial con-
ﬁguration is necessary to provide circulatory support. The
traditional conﬁguration for venoarterial ECMO involves
femoral venous drainage and femoral arterial reinfusion.
With this conﬁguration, the reinfusion jet ﬂows retrograde
up the aorta and may meet resistance from antegrade ﬂow
generated by the left ventricle (Fig. 3). Depending on the
amount of native cardiac function, the location of the
interface between antegrade and retrograde ﬂow will vary,
and in circumstances in which there is impaired native gas
exchange with a signiﬁcant amount of poorly oxygenated
blood ejected from the left ventricle, the oxygenated, rein-
fused blood may not reach the aortic arch from below,
thereby rendering oxygen delivery to the cerebral and coro-
nary vascular beds suboptimal. In such patients, an addi-
tional reinfusion cannula may be added to the conﬁguration
with a “Y” connection off of the femoral arterial reinfusion
cannula, with insertion into an internal jugular vein. This
conﬁguration of venous drainage combined with both
arterial and venous return (venoarterial-venous ECMO)
may facilitate oxygenation of the cerebral and coronary
circulation by returning oxygenated blood into the nativecardiac circulation while providing circulatory support. In
cases of severe left ventricular dysfunction, venoarterial
ECMO may result in overdistention of the left ventricle
and worsening pulmonary edema (15). Several approaches
have been described to facilitate left ventricular decom-
pression (16,17).
ECMO cannulation has traditionally been performed in
the operating room by cardiothoracic surgeons, because they
are best suited to perform cut-down procedures for cannu-
lation and manage complications requiring surgical inter-
vention (5,18). However, with a general trend toward
percutaneous approaches, cannulation is being performed
Figure 3 Femoral Venoarterial ECMO
When extracorporeal membrane oxygenation (ECMO) is implemented via femoral
venous drainage and femoral arterial return in patients with residual native cardiac
function and impaired lung function, reinfused oxygenated blood (red arrow),
ﬂowing retrograde through the aorta, may meet resistance from poorly oxygenated
blood ﬂowing antegrade from the left ventricle (purple arrow). Depending on the
amount of cardiac function, the location of the interface between antegrade and
retrograde ﬂow will vary, and the reinfused oxygenated blood may not reach the
cerebral and coronary vascular beds.
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2771more frequently by interventional cardiologists, anesthesi-
ologists, and medical intensivists, among others. Regardless,
management of the extracorporeal circuit requires a multi-
disciplinary team (19,20).Indications and Evidence
ECMO for Respiratory Failure
Acute respiratory distress syndrome. The most exten-
sively studied respiratory indication for ECMO is acute
respiratory distress syndrome (ARDS) (9) (Table 1). In
circumstances in which invasive mechanical ventilation isTable 1 Indications and Highest Level of Evidenc
Respiratory
ARDS
Hypercapnic respiratory failure
Bridge to lung transplantation
Primary graft dysfunction after lung transp
Cardiac
Myocardial infarction–associated cardiogen
Fulminant myocarditis
Sepsis-associated cardiomyopathy
Pulmonary hypertension
Extracorporeal cardiopulmonary resuscitati
Post-cardiotomy cardiogenic shock
Primary graft failure after heart transplant
Bridge to VAD implantation or heart transp
Prevention of acute right ventricular failure
LVAD implantation
ARDS ¼ acute respiratory distress syndrome; ECMO ¼ extracorporeal me
ventricular assist device.necessary to support gas exchange, positive-pressure venti-
lation may potentiate lung injury (21). The only ventilation
strategy proved to reduce mortality in ARDS is a volume-
and pressure-limited ventilation strategy (22). ECMO has
the potential to improve outcomes in patients with ARDS
by providing adequate oxygenation while facilitating lung-
protective ventilation by correcting unsustainable levels of
hypercapnia and respiratory acidosis that may accompany
low–tidal volume ventilation (23). Potential indications for
ECMO in the setting of ARDS have been proposed (9).
Early randomized trials were unsuccessful in demon-
strating a survival beneﬁt from ECMO in patients with
severe forms of ARDS (1,2). More recently, the impact of
modern extracorporeal support on survival in patients with
severe ARDS was evaluated in the Conventional Ventilation
or ECMO for Severe Adult Respiratory Failure trial, in
which 180 subjects with severe, potentially reversible respi-
ratory failure were randomized to conventional mechanical
ventilation or referral to a specialized center for consider-
ation of ECMO (24). Compared with the conventionally
managed group, those referred for consideration of ECMO
had a signiﬁcantly lower rate of death or severe disability
at 6 months (37% vs. 53%; relative risk: 0.69; p ¼ 0.03).
However, a lung-protective ventilation strategy was not
mandated for the control group, and only 70% of those
patients received such a strategy at any time during the
study. Additionally, only 76% of those referred for ECMO
actually received it, making it difﬁcult to evaluate the effect
of ECMO alone on survival. Other nonrandomized obser-
vational studies, particularly during the inﬂuenza A (H1N1)
pandemic in 2009, have shown conﬂicting results of the
impact of ECMO on survival in severe ARDS (25). Results
from propensity analyses in the United Kingdom suggested a
mortality beneﬁt from ECMO when ECMO-referred pa-
tients with severe inﬂuenza-related ARDS were compared
with a similar cohort of patients in whom ECMO was not
considered (24% vs. 47%; relative risk: 0.51; 95% conﬁdencee for ECMO in Cardiopulmonary Disease
Randomized controlled trials
Prospective feasibility studies
Cohort studies
lantation Cohort studies
ic shock Cohort studies
Cohort studies
Case series
Case series
on Cohort studies with propensity analyses
Cohort studies
ation Cohort studies
lantation Cohort studies
after Cohort studies
mbrane oxygenation; LVAD ¼ left ventricular assist device; VAD ¼
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2772interval: 0.31 to 0.84; p ¼ 0.008) (26). However, a similar
analysis in a distinct French cohort found nomortality beneﬁt
from ECMO (27). Additionally, compared with centers at
which ECMO was used for H1N1-associated ARDS, a
single-center study reported a comparably high rate of success
with the use of conventional mechanical ventilation alone in
patients with similar degrees of hypoxemia (28). Such dis-
crepancies highlight the need for a prospective, randomized
controlled trial evaluating the effect of ECMO on survival in
severe ARDS. Such a trial is currently underway, (EOLIA
[Extracorporeal Membrane Oxygenation for Severe Acute
Respiratory Distress Syndrome]) (29). Mortality risk predic-
tion models have been proposed to risk-stratify patients with
severe ARDS receiving venovenous ECMO and may help
identify those patients most appropriate for extracorporeal
support (30,31). In addition to the evaluation of short-term
outcomes, more data are needed to assess the long-term
neurocognitive, psychiatric, and functional outcomes of
those who recover from ARDS having received ECMO.
Beyond facilitating gas exchange and adherence to lung-
protective ventilation, ECMO may have the beneﬁt of
reducing lung injury even further by facilitating the appli-
cation of very low tidal volumes and airway pressures, as well
as a reduction in respiratory rate, an approach sometimes
referred to as “lung rest” (32–34). Such an approach has been
widely used in patients with severe ARDS receiving ECMO.
However, future applications of very lung-protective ventila-
tion strategies may extend to less severe cases of ARDS
through the use of ECCO2R, without the need for the
higher blood ﬂow rates of ECMO to provide oxygenation.
Post-hoc analysis of a recent clinical trial comparing
ECCO2R-assisted very low tidal volume ventilation
(approximately 3 ml/kg predicted body weight) with con-
ventional low–tidal volume ventilation in patients with
moderate to severe ARDS demonstrated more ventilator-
free days for the very low tidal volume group (40.9 vs.
28.2; p ¼ 0.033) among those with more severe hypoxemia
(34). The role of ECMO or ECCO2R in patients with
less severe ARDS, with hypercapnia and acidemia limiting
the application of low–tidal volume ventilation, has yet to
be deﬁned and is the focus of a trial that is currently in the
planning phases. Likewise, larger prospective studies are
needed to better deﬁne the role of very lung-protective
ventilation and whether such a strategy translates into
reduced lung injury and improved clinical outcomes.
Hypercapnic respiratory failure. With an improved risk-
beneﬁt ratio, there is great potential to use ECCO2R to
manage hypercapnic respiratory failure, thereby minimizing
or even eliminating the need for a ventilator. In chronic
obstructive pulmonary disease, invasive mechanical ventila-
tion is associated with multiple complications, including
dynamic hyperinﬂation and elevations in intrinsic positive
end-expiratory pressure, ventilator-associated pneumonia,
and impaired delivery of aerosolized medications (35,36).
Several small case series have demonstrated the feasibilityof avoidance of or rapid weaning from invasive mechanical
ventilation, with ECCO2R used to manage gas exchange
(37–39). With correction of hypercapnia and respiratory
acidosis, dyspnea and work of breathing rapidly improve,
facilitating early mobilization (39). Although early mobili-
zation has been described with invasive mechanical venti-
lation (40), it is more likely to be successful with the
substitution of ECCO2R for mechanical ventilation
because of the signiﬁcant improvement in dyspnea that is
seen with ECCO2R compared with mechanical ventilation
in the hypercapnic population (39). The risks of ECCO2R
must be weighed against the beneﬁt of minimizing invasive
mechanical ventilation, and additional studies are required
to deﬁne the ideal patient population and the economic
impact of such a strategy before it can be recommended
for clinical use. Similarly, ECCO2R may be considered in
other forms of hypercapnic respiratory failure, including
refractory status asthmaticus, in which the ability to avoid
invasive mechanical ventilation altogether is potentially
advantageous (41,42).
Bridge to lung transplantation and post-transplantation
primary graft dysfunction. Although ECMO has tradi-
tionally been considered a relative contraindication to lung
transplantation because of poor perioperative outcomes
(43), more recent studies have reported excellent post-
transplantation survival, especially at centers with more
extensive experience (44,45). With the potential for ECMO
to provide sufﬁcient gas exchange to supplant the ventilator,
a nonintubated ECMO strategy may be considered for some
transplantation candidates who would otherwise be venti-
lator dependent, a population with poor outcomes related to
ventilator-associated complications (46). Outcomes may be
further optimized when such a strategy is combined with
active physical therapy and should be considered in patients
who would otherwise be inactivated from the transplantation
list because of deconditioning. This is particularly true for
those patients in whom ECMO or ECCO2R alleviates
dyspnea sufﬁciently to permit rehabilitation (45,47,48). A
major limitation to the use of ECMO for end-stage respi-
ratory failure is the lack of a destination device therapy, with
ECMO remaining an intervention for which an intensive
care unit is required.
In severe cases of primary graft dysfunction, a form of
acute lung injury that is the leading cause of early death after
lung transplantation (49), ECMO may be used to support
gas exchange while the allograft recovers. Studies have des-
cribed similar survival in cases of ECMO-supported severe
primary graft dysfunction compared with those with less
severe primary graft dysfunction without ECMO support,
particularly when instituted early (50). However, ECMO
has not been shown to affect long-term allograft function.
ECMO for Cardiac Failure
Cardiogenic shock. Cardiogenic shock, deﬁned as
myocardial contractile dysfunction, low cardiac output, and
JACC Vol. 63, No. 25, 2014 Abrams et al.
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2773tissue hypoperfusion, may be the consequence of an acute
ischemic event or a nonischemic process, with or without
underlying chronic heart failure. Medical therapies, con-
sisting primarily of inotropic agents and vasopressors, may
improve cardiac output at the expense of increased
myocardial oxygen demand, myocardial ischemia, arrhyth-
mogenicity, and compromise of tissue microcirculation and
may be associated with increased risk for mortality (51).
Mechanical circulatory support systems, with venoarterial
ECMO being one of several percutaneous approaches, have
the potential to attenuate the inﬂammatory response by
improving tissue perfusion without the adverse conse-
quences of medical therapies, creating the opportunity to
reduce the high mortality rates currently associated with
conventionally managed cardiogenic shock. The advantage
of ECMO over other percutaneous devicesdintra-aortic
balloon counterpulsation devices, the TandemHeart left
ventricular assist device (LVAD) (CardiacAssist, Inc.,
Pittsburgh, Pennsylvania), and Impella devices (Abiomed,
Danvers, Massachusetts)daccrues from the rapidity of
insertion; the ability to support right ventricular, left ven-
tricular, or biventricular failure at high blood ﬂow rates; and
the potential to support patients with concomitant lung
injury when needed (52).
Cardiogenic shock complicating acute myocardial
infarction. There are no randomized controlled trials
comparing ECMO with other mechanical support systems
in myocardial infarction–associated cardiogenic shock, but
several nonrandomized studies suggest a survival advantage
from the early use of ECMO in such circumstances (53,54).
In an observational study of patients with ST-segment
elevation myocardial infarction–related cardiogenic shock
undergoing percutaneous coronary intervention (PCI) with
and without ECMO support, those receiving ECMO
had signiﬁcantly lower 30-day mortality (39.1% vs. 72%;
p ¼ 0.008) (54). Interpretation of these data is limited by the
fact that cohorts were enrolled over different time frames
(1993 to 2002 for the non-ECMO cohort vs. 2002 to 2009
for the ECMO cohort), potentially leading to discrepancies
in treatment between groups, especially given that coronary
stents were unavailable at the study center before 1998.
Higher rates of Thrombolysis In Myocardial Infarction ﬂow
grade 3 achieved in the ECMO group may reﬂect improved
hemodynamic stability in the catheterization laboratory or,
alternatively, may be a consequence of improved PCI tech-
nique over time. Ultimately, randomized controlled trials are
needed to determine the true beneﬁt, if any, of ECMO in
myocardial infarction–associated cardiogenic shock.
Fulminant myocarditis. ECMO use has been investigated
as a modality to support nonischemic cardiogenic shock,
including fulminant myocarditis (55–58). Patients with
fulminant myocarditis who are successfully bridged with
ECMO to recovery may have long-term prognoses com-
parable with those of hemodynamically stable patients
with acute myocarditis (55). In 1 cohort of patients whoreceived either a biventricular assist device (n ¼ 6) or
ECMO (n ¼ 35) for fulminant myocarditis with refractory
cardiogenic shock, overall intensive care unit survival was
68%, with higher severity of illness and elevated cardiac
biomarkers serving as independent predictors of mortality
and an inability to wean from ECMO (57). ECMO may be
as efﬁcacious as a ventricular assist device (VAD) while
having the advantage of being less invasive. In a study
comparing ECMO with biventricular assist devices for
fulminant myocarditis, those receiving ECMO had com-
parable rates of weaning from device therapy and survival to
hospital discharge without the need for transplantation
(83% vs. 80%) and more rapid improvement in renal and
hepatic laboratory proﬁles, despite having a higher severity
of illness and worse left ventricular function before device
implantation (58).
Sepsis-associated cardiomyopathy. Myocardial depression
is a well-recognized consequence of severe septic shock (59).
There are emerging data suggesting that ECMO may have a
role in supporting patients who develop refractory cardiac
failure in this setting (60,61). Larger studies are needed to
determine whether the beneﬁt of ECMO outweighs the
risk, especially in cases in which septic shock is complicated
by marked disturbances in coagulation.
Pulmonary hypertension. ECMO is an emerging man-
agement option in patients with decompensated pulmonary
hypertension with concomitant right ventricular failure,
particularly when there is an acutely reversible process,
medical management has not been optimized, or lung
transplantation is a consideration (62). ECMO for this
indication typically requires a femoral venoarterial conﬁg-
uration to bypass the high resistance of the pulmonary
vasculature and decompress the right ventricle. However, 3
conﬁgurations have been used to avoid femoral cannulation.
Internal jugular venous drainage may be combined with
subclavian arterial reinfusion (18) (Fig. 4). In patients with
pre-existing intra-atrial defects, a dual-lumen cannula may
be oriented with the reinfusion jet directed across the
defect (rather than across the tricuspid valve), effectively
providing an oxygenated right-to-left shunt while decom-
pressing the right ventricle (63,64). Additionally, arte-
riovenous ECMO can be inserted between the main
pulmonary artery and the left atrium, though this typically
requires a sternotomy (65). When ECMO is initiated as a
bridge to recovery, pulmonary vasodilators may be opti-
mized while the underlying acute process is treated (62).
When the goal of ECMO is to bridge to transplantation,
pulmonary vasodilators may be down-titrated to preferen-
tially shunt blood through the extracorporeal circuit and away
from the high-resistance pulmonary vasculature, thereby
optimizing systemic oxygenation (66). Reducing the dosage
of intravenous pulmonary vasodilators will also minimize the
degree of systemic vasodilation that may occur as the medi-
cations pass through the ECMO circuit and into the arterial
circulation.
Figure 4
Venoarterial ECMO With Internal Jugular Venous
Drainage and Subclavian Arterial Reinfusion
An alternative approach to femoral venoarterial extracorporeal membrane
oxygenation (ECMO) is drainage from the internal jugular vein and reinfusion into
the subclavian artery through an end-to-side graft. The graft and arterial cannula
are oriented such that reinfused blood is directed toward the aorta. In contrast to
femoral venoarterial ECMO, this conﬁguration ensures the delivery of oxygenated
blood to the aortic arch and, consequently, the cerebral and coronary vasculature.
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2774Pulmonary embolism. Massive pulmonary embolism may
likewise beneﬁt from ECMO. A retrospective single-center
review of ECMO for massive pulmonary embolism,
including patients in active cardiac arrest, demonstrated 62%
overall survival when combined with anticoagulation or
surgical embolectomy (67). The combination of ECMO,
thrombolysis, and catheter-directed thrombectomy or em-
bolus fragmentation has also been reported, with 30-day
survival of 70% (68).
Extracorporeal cardiopulmonary resuscitation. “Extra-
corporeal cardiopulmonary resuscitation” (ECPR) is the
term used to describe the institution of extracorporeal sup-
port to restore circulation during cardiac arrest. Although
there are no randomized controlled trials investigating the
efﬁcacy of ECPR for cardiac arrest, its use has been steadily
increasing (69–72). In a prospective, observational study of
witnessed in-hospital cardiac arrests, propensity analysis
matching 46 subjects who received conventional cardiopul-
monary resuscitation (CPR) with 46 subjects who received
ECPR demonstrated signiﬁcantly higher survival at dis-
charge in the ECPR group (32.6% vs. 17.4%; p < 0.0001)
and at 1 year (hazard ratio: 0.53; p ¼ 0.006) (69), with a
trend toward improved neurological outcomes. In multi-
variate analysis, an initial rhythm of ventricular ﬁbrillation or
ventricular tachycardia and use of ECPR were positively
associated with survival to discharge. A more recent pro-
pensity analysis of patients who experienced in-hospital
cardiac arrest demonstrated signiﬁcantly higher 2-year sur-
vival with minimal neurological impairment in those treated
with ECPR compared with conventional CPR (20% vs. 5%;
p ¼ 0.002). Independent predictors associated with minimal
neurological impairment included age <65 years, CPRduration <35 min, and subsequent cardiovascular inter-
vention (71). Regarding out-of-hospital cardiac arrests, a
recent matched propensity analysis demonstrated signiﬁ-
cantly higher neurologically intact survival at 3 months in
those who received ECPR compared with conventional
CPR (29.2% vs. 8.3%; p ¼ 0.018) (72).
With the ability of ECMO to both maintain systemic
circulation during cardiac arrest and increase coronary per-
fusion pressure, the combination of ECPR and intra-arrest
PCI may greatly improve the likelihood of successful deﬁ-
brillation and recovery in cardiac arrest due to an acute
coronary syndrome. A multicenter nonrandomized study
demonstrated the feasibility of combining ECMO and
emergency coronary angiography in 81 subjects, 61 of whom
received intra-arrest PCI (73). Compared with those who
received ECMO and coronary angiography without PCI,
those receiving PCI achieved higher rates of resumption
of spontaneous beating (100% vs. 60%; p < 0.001), weaning
from ECMO (59% vs. 28%; p ¼ 0.009), 30-day survival
(36% vs. 12%; p ¼ 0.03), and favorable neurological out-
comes (33% vs. 4%; p ¼ 0.005). In-hospital (vs. out-of-
hospital) cardiac arrest and shorter duration from collapse to
initiation of ECMO were correlated with 30-day survival.
Although observational trials suggest a possible survival
advantage of ECPR over conventional CPR, overall survival
remains relatively low. More research is needed to deﬁne
the patient population that would derive the greatest beneﬁt
from extracorporeal resuscitation, with an emphasis on
survival with minimal neurological impairment.
The 2010 American Heart Association guidelines for
cardiopulmonary resuscitation and emergency cardiovascular
care do not recommend the routine use of ECPR for cardiac
arrest. However, ECPR may be considered when the time
without spontaneous circulation is short, resuscitation at-
tempts are adequate, and the cause of cardiac arrest is
potentially reversible (74). The guidelines emphasize that
ECPR use should be restricted to centers at which it is
readily available and that its initiation and management
require highly trained personnel and specialized equipment.
Post-operative cardiogenic shock and post-transplant
primary graft failure. Post-cardiotomy cardiogenic shock is
an uncommon but highly lethal complication of cardiac
surgery. ECMO may be considered as temporary support
post-operatively, particularly when unable to wean from car-
diopulmonary bypass in the operating room (75).Mortality in
patients requiring this level of support remains high (76).
Primary graft failure (PGF) is a well-recognized compli-
cation of heart transplantation associated with a high mor-
tality, for which ECMO has been used as temporary support
(77,78). As expected, overall survival for patients with PGF
requiring ECMO is worse than in those who do not develop
PGF. However, patients with ECMO-supported PGF who
survive beyond the early post-transplantation period have
comparable long-term survival with non-PGF transplant
recipients (78,79).
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2775Bridge to VAD implantation or heart transplantation.
VADs may be used as a bridging therapy to heart trans-
plantation in appropriately selected patients with severe car-
diac dysfunction (51), with the advantage of being able to
function as destination devices if transplantation is not
feasible. ECMO has also been reported as a bridging therapy
to heart transplantation or VAD implantation or as a bridge
to decision when prognosis is uncertain (80–82). However,
the duration of support that can be provided is shorter than
for VADs, making transplantation or transition to VAD of
greater urgency, and patients receiving ECMO support must
remain within an intensive care unit (82). Success of ECMO
bridging varies greatly and depends in large part on pre-
ECMO patient characteristics and organ availability in the
cases in which transplantation is the goal. In a retrospective
review of 70 patients in whom ECMO was used as a bridge
to heart transplantation, 31 (44%) were bridged to either
heart transplantation (n ¼ 15) or VAD implantation (n ¼
16), though only 11 (73%) and 8 (50%) of the heart transplant
and VAD recipients, respectively, survived to hospital
discharge, highlighting the limitations of bridging therapy in
this highly morbid patient population (80). Age > 50 years,
CPR before ECMO initiation, and high sequential organ
failure assessment score were independent predictors of un-
successful bridging. Pre-implantation CPR as a predictor of
poor outcomes was corroborated in a more recent single-center
study of 90 patients who received mechanical circulatory sup-
port (VAD or ECMO) for refractory cardiogenic shock (83).
Forty-nine percent received short-term VAD support as a
bridge to decision, and 51% received ECMO when neuro-
logical status was uncertain or there was complete hemody-
namic collapse or severe coagulopathy. Overall survival was
49%, with 26% of patients transitioned to implantable VADs,
18% recovering sufﬁcient native cardiac function, and 11%
bridged to transplantation. CPR at the time of implantation
was an independent predictor of in-hospital mortality (odds
ratio: 5.79; p ¼ 0.022). These studies highlight the need
for careful consideration of relative and absolute contraindica-
tions to mechanical circulatory support. In particular, ECMO
for cardiogenic shock superimposed on chronic cardiomyopa-
thy may be associated with particularly poor outcomes (84).
ECMO to prevent acute right ventricular failure
after LVAD implantation. Both femoral venoarterial
ECMO and percutaneous venous-to-pulmonary arterial
ECMO have been successfully used to provide right ven-
tricular support in patients with biventricular dysfunction
undergoing LVAD implantation (85,86). In this setting,
ECMO can allow time for the already compromised right
ventricle to get accustomed to the increasing preload,
thereby avoiding distension and right ventricular failure
leading to poor ﬁlling of the LVAD.
Complications
The beneﬁts of ECMO must be weighed against its
inherent risks. Hemorrhagic complications are among themost commonly reported adverse events (8). The use of
lower levels of anticoagulation mitigates the extent of
bleeding, with some centers targeting activated partial
thromboplastin times as low as 40 to 60 s (3). There are,
however, no universally accepted anticoagulation protocols,
and anticoagulation needs to be adjusted to the speciﬁc
needs of the individual patient. Thromboses, either within
the circuit or related to the indwelling portions of the
cannulae, pose an embolic risk to the patient, which, in the
case of venoarterial ECMO or venovenous ECMO in the
presence of interatrial defect, may result in stroke. Infectious
complications have been reported to varying degrees, with
some reports indicating longer durations of mechanical
ventilation, ECMO support, and hospital stays associated
with infection (8,87). Limb ischemia and compartment
syndrome are of concern in venoarterial ECMO. The
insertion of a distal reperfusion cannula into the superﬁcial
femoral artery or the use of an end-to-side graft may be
considered to optimize blood ﬂow to the extremity
(18,88,89). Other complications that have been asso-
ciated with ECMO include hemolysis, thrombocytopenia,
acquired von Willebrand syndrome, disseminated intravas-
cular coagulopathy, and air embolism (8,90). In a recent
meta-analysis incorporating 1,866 patients from 20 studies of
ECMO for cardiogenic shock or cardiac arrest between 2000
and 2012, complication rates were reported as follows: lower
extremity ischemia, 16.9%; fasciotomy or compartment
syndrome, 10.3%; lower extremity amputation, 4.7%; stroke,
5.9%; major or signiﬁcant bleeding, 40.8%; rethoracotomy
for post-cardiotomy bleeding or tamponade, 41.9%; and
signiﬁcant infection, 30.4% (91). Cardiac or major vascular
perforation is a rare but potentially lethal complication of
cannulation, the frequency of which depends on the type of
cannula used (92). Ultimately, complication rates will vary
according to institutional experience and patient selection.
Future Directions
Early Mobilization
Physical therapy in critically ill patients is increasingly being
recognized not only as safe but also as a signiﬁcant determi-
nant of important clinical outcomes (40,93). As ECMO
circuits become more compact, femoral cannulation is avoi-
ded, and invasivemechanical ventilatory support is minimized
or eliminated, active rehabilitation, including ambulation,
becomes more feasible (39,45,62,94–96) (Fig. 5). Physical
therapy is particularly important in pre-transplantation pa-
tients to prevent deconditioning and maintain transplant
candidacy.
ECMO as Destination Therapy for Respiratory Failure
Although ECMOmay serve as bridging therapy to recovery,
VAD implantation, or transplantation in cardiac failure, it
can currently serve only as bridging therapy to recovery or
transplantation in respiratory failure, without any existing
destination device. Advances in ECMO technology,
Figure 5 ECMO in the Ambulatory Patient
Upper-body conﬁgurations and compact circuits facilitate mobilization in patients
with respiratory failure requiring extracorporeal membrane oxygenation (ECMO).
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exchange membranes, are moving the ﬁeld toward the
development of a portable extracorporeal gas exchange de-
vice, effectively an artiﬁcial lung, with the potential to create a
true paradigm shift in the management of respiratory failure.
Need for Additional Studies
Despite the increasing popularity of ECMO in cardiopul-
monary disease, many questions remain about the optimal
patient populations in which it should be deployed. The
most robust evidence for ECMO in respiratory failure is a
randomized controlled trial with signiﬁcant limitations in
interpretation inherent in the study design. In cardiac dis-
ease, the highest level of evidence is limited to cohort studies
with propensity analyses (Table 1). Larger, randomized
controlled trials, such as Extracorporeal Membrane
Oxygenation for Severe Acute Respiratory Distress Syn-
drome, are necessary to best evaluate many of the uses of this
technology and compare them with existing therapeutic
options for cardiopulmonary failure (97). These studies
should ideally incorporate cost-beneﬁt analyses to best un-
derstand the economic impact of such a resource-intensive
intervention. In the absence of higher-quality evidence,
ECMO has not been incorporated into the major cardiac
and pulmonary practice guidelines. General practice guide-
lines for the use and management of ECMO in cardiopul-
monary disease are provided by the Extracorporeal Life
Support Organization (98).Conclusions
Signiﬁcant advances in extracorporeal technology have led to
more widespread use of ECMO for severe respiratory or
cardiac failure. More data are ultimately needed to under-
stand the appropriate role of ECMO for its various poten-
tial indications. Likewise, the use of ECMO may introduce
numerous ethical dilemmas to practice (99,100). As addi-
tional technological advances are made, ECMO has the
potential to signiﬁcantly alter current management para-
digms for severe cardiac and respiratory disease.
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